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Aims: Continuous glucose monitoring (CGM) parameters, self-monitored blood glucose
(SMBG), HbA1c and oral glucose tolerance test (OGTT) were studied during preclinical type
1 diabetes mellitus.
Methods: Ten asymptomatic children with multiple (P2) islet autoantibodies (cases) and 10
age and sex-matched autoantibody-negative controls from the Type 1 Diabetes Prediction
and Prevention (DIPP) Study were invited to 7-day CGM with Dexcom G4 Platinum Sensor.
HbA1c and two daily SMBG values (morning and evening) were analyzed. Five-point OGTTs
were performed and carbohydrate intake was assessed by food records. The matched pairs
were compared with the paired sample t-test.
Results: The cases showed higher mean values and higher variation in glucose levels during
CGM compared to the controls. The time spent P7.8 mmol/l was 5.8% in the cases com-
pared to 0.4% in the controls (p = 0.040). Postprandial CGM values were similar except after
the dinner (6.6 mmol/l in cases vs. 6.1 mmol/l in controls; p = 0.023). When analyzing the
SMBG values higher mean level, higher evening levels, as well as higher variation were
observed in the cases when compared to the controls. HbA1c was significantly higher in
the cases [5.7% (39 mmol/mol) vs. 5.3% (34 mmol/mol); p = 0.045]. No differences were
observed in glucose or C-peptide levels during OGTT. Daily carbohydrate intake was slightly
higher in the cases (254.2 g vs. 217.7 g; p = 0.034).
Conclusions: Glucose levels measured by CGM and SMBG are useful indicators of dysg-
lycemia during preclinical type 1 diabetes mellitus. Increased evening glucose values seem
to be common in children with preclinical type 1 diabetes mellitus.
 2016 Elsevier Ireland Ltd. All rights reserved.FIN-90014,
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Type 1 diabetes mellitus is a chronic autoimmune disease
characterized by immune-mediated destruction of the pan-
creatic b-cells. The incidence of type 1 diabetes mellitus has
been increasing worldwide, with the highest rate observed
in Finland [1–3]. The preclinical phase of the disease can be
identified through the presence of autoantibodies to pancre-
atic b-cell antigens [4]. Confirmed positivity for P2 biochem-
ical islet autoantibodies provide a cumulative risk of more
than 80% during follow up for 15 years in children with
HLA-conferred disease susceptibility [5,6].
The characteristics of glucose metabolism during the pre-
clinical phase of type 1 diabetes mellitus have so far been
monitored using oral and intravenous glucose tolerance tests
(OGTTand IVGTT, respectively) which show deteriorating glu-
cose tolerance and insulin secretion in high-risk children as
the disease progresses [7–11]. It has been previously shown
that HbA1c values start to rise as early as 2 years before the
diagnosis of type 1 diabetes mellitus [12], and reported that
HbA1c, OGTT and randomly measured plasma glucose values
are useful in the prediction of the timing of the diagnosis in
high-risk children [9,12,13].
Continuous glucose monitoring (CGM) is becoming more
common in patients with clinical type 1 diabetes mellitus to
monitor glycemic management. Regular CGM is associated
with improved glucose levels, although the benefit seems to
depend on target population [14,15]. In preclinical type 1 dia-
betes mellitus CGM might be helpful in the identification of
individuals at high risk for progressing to overt disease in
the near future [16–18]. Early identification of children with
deteriorating glucose tolerance may prevent acute complica-
tions at clinical diagnosis. CGM could also be used to monitor
glucose excursions in clinical trials aimed at secondary pre-
vention of type 1 diabetes mellitus [19].
In this study the aim was to characterize the differences in
glucose metabolism by using 7-day CGM combined with food
records and calibration with self-monitored blood glucose
(SMBG), HbA1c and five-point OGTT with glucose and
C-peptide analyses in children with increased class II HLA
associated genetic risk for type 1 diabetes mellitus and
multiple (P2) biochemical islet autoantibodies in comparison
with age- and sex-matched controls carrying a risk-conferring
HLA class II genotype but testing negative for autoantibodies.
2. Methods
2.1. Study design
The Type 1 Diabetes Prediction and Prevention Study (DIPP) is
a Finnish population-based cohort study in which genetically
predisposed children are followed since birth for islet autoan-
tibodies [20–22]. The current analysis included 10 children
with preclinical type 1 diabetes mellitus (cases) defined as
carrying HLA-conferred disease susceptibility and testing
positive for at least two positive biochemical autoantibodies
(insulin autoantibodies [IAA], GAD antibodies [GADA] or
antibodies to the insulinoma-2 associated antigen [IA-2A]),and 10 age- and sex-matched control children with HLA-
defined predisposition to type 1 diabetes mellitus but no
autoantibodies. Autoantibodies were analyzed as previously
described [6]. The age at seroconversion was defined as the
age when at least one of the biochemical (IAA, GADA, IA-2A)
islet autoantibodies was detected for the first time. The age
at positivity for multiple autoantibodies was defined as the
time point, when at least two biochemical islet autoantibod-
ies were detected in the same sample. All CGMs were per-
formed between March 2014 and February 2015. The study
was approved by the Ethics Committee of the Oulu University
Hospital, Oulu, Finland. All families participating in the study
provided written informed consent.
2.2. Continuous glucose monitoring
Ten children with multiple biochemical islet autoantibodies
were invited to continuous glucose monitoring with Dexcom
G4 PLATINUM CGM (San Diego, CA) for one week. Age
(±12 months) and sex-matched controls were also monitored
for one week for paired comparison. When recruiting the
study population the acceptance rate was 48% for case chil-
dren and 36% for control children. CGM was started only in
healthy children with no signs of acute infection. The use of
the device was blinded during the study, so the participants
were not able to see real-time CGM readings. The participants
calibrated the device with self-monitored blood glucose val-
ues twice a day with a blood glucose meter according to the
manufacturer’s instructions. The families were asked to mea-
sure the child’s SMBG every morning and evening with no
special instructions related to meals. All the children were
also invited to a five-point OGTT either at the beginning, or
at the end of the CGM period. During the OGTT plasma glu-
cose and C-peptide values were analyzed at 0, 30, 60, 90 and
120 min and a sample for HbA1c measurement was also
taken. Body weight and height were measured and ISO-BMI
was calculated for every participant at the beginning of the
follow-up week [23]. The families were asked to keep food
records during the seven days of CGM monitoring with pre-
cise timing of all meals and registration of all consumed nour-
ishments. The study physician recruited the participants and
installed the CGM device, and also gave guidance on the use
of the Dexcom G4 Platinum glucose monitor, SMBG and food
records. After the CGM period the physician reviewed the glu-
cose results with the families.2.3. Devices
All participants used the Dexcom G4 Platinum CGM equip-
ment for which good accuracy and good patient experiences
have been reported previously [24]. OGTT plasma glucose
and C-peptide concentrations were measured in the Oulu
University Hospital Laboratory. The hexokinase method was
used for plasma glucose and a chemiluminescence method
for C-peptide. HbA1c was analyzed with Advia 1800 (Siemens,
Munich, Germany). SMBG was measured with the Bayer
Contour glucometer (Bayer, Leverkusen, Germany) using the
hexokinase based method.
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The first 12 h of the CGM registration were discarded from the
analyses to exclude possible false signals during the start of
the monitoring. Primary variables given by the Dexcom device
were the mean, minimum, maximum, standard deviation
(SD), range of glucose values, time spent at or over a glucose
value of 7.8 mmol/l, and time spent at or over 11.1 mmol/l.
These cut-off values were chosen according to the WHO rec-
ommendations for impaired glucose tolerance and diabetes
mellitus in an OGTT [25]. Glucose values at or over
7.8 mmol/l have been shown to be uncommon in healthy
individuals [26]. Area under the curve (AUC) for the glucose
values was calculated by the trapezoidal rule. The mean
amplitude of glycemic excursion (MAGE) was calculated as
previously described [27]. In addition, the postprandial glu-
cose values (peak, mean, minimum, maximum, SD) were reg-
istered from the CGM data 2 h after each meal for the
analyses. Day time was defined as between 6:00 am and mid-
night, and night time between midnight and 6:00 am. The
daily amount of consumed carbohydrates was calculated
from the list of consumed nutrients registered by the families
(quality and quantity, time of intake) for every meal (break-
fast, lunch, dinner and supper) during the study week. Snacks
were also included in the total daily carbohydrates. Individual
means of all tested parameters during the follow-up week
were calculated and the statistical comparison was
made with the paired sample t-test between the matched
pairs. Spearman’s rho was used to analyze the correlation
between time since becoming positive for islet autoantibodies
and markers of dysglycemia. Statistical significance was
set at p < 0.05. All analyses were performed using
IBM SPSS Statistics for Windows (version 22.0; SPSS,
Chicago, IL).
3. Results
3.1. Patient baseline characteristics
The baseline characteristics of the children with a risk-
associated class II HLA genotype and multiple islet autoanti-
bodies (cases) and their age- and sex-matched controls with
class II HLA-conferred risk for type 1 diabetes mellitus butTable 1 – Baseline characteristics of 10 age- and sex-matched ch
type 1 diabetes mellitus and multiple biochemical islet auto-an
class II HLA-associated genetic risk but no autoantibodies (cont
Number of children
Mean age, years (SD)
Boys, n
Mean age at seroconversion, years (SD)
Mean age at multiple (P2) autoantibodies, years (SD)
ISO-BMI*, kg/m2 (SD)
Mean duration of CGM, days (SD)
Mean number of SMBG values/day, n (SD)
* ISO-BMI is age and sex-adjusted body mass index reflecting the expecno autoantibodies are shown in Table 1. Baseline characteris-
tics showed no significant differences between the case and
control groups. All ten pairs completed the CGM-follow-up,
seven pairs had measured HbA1c values, five pairs had OGTT
results and eight pairs completed the food records.
3.2. CGM and SMBG values
The mean seven day CGM glucose level was higher in the
cases, as were the day and night time CGM values (Table 2).
The case children had also higher maximal CGM values and
AUC for glucose. Higher variation in the CGM values was
observed in the case children, with significant differences in
the range (p = 0.032), standard deviation (p = 0.040) and MAGE
(p = 0.031). The proportion of time spent at glucose levels
P7.8 mmol/l was higher in the cases, 5.8% vs. 0.4%, (95% CI
of the difference 0.3–10.4, p = 0.040), but no difference was
observed for the time spent at glucose levels P11.1 mmol/l
(p = 0.152).
When comparing the twice daily measured SMBG values
the cases had higher mean glucose values in the evening
(p = 0.029), higher maximum glucose values (p = 0.038) and
higher glucose variability defined by the standard deviation
of all SMBG values (p = 0.020); Table 2.
The clinically most relevant CGM and SMBG values are
presented in Fig. 1.
Postprandial glucose values were also analyzed from the
CGM data. The only significant difference in postprandial glu-
cose values was observed in the peak glucose after dinner
[6.6 mmol/l (SD 0.5) in the cases compared to 6.1 mmol/l (SD
0.4) in the controls; 95% CI of the difference 0.1 to 1.0,
p = 0.023] (Table 2).
3.3. HbA1c and OGTT
The mean HbA1c was 5.7% (39 mmol/mol) in the cases and
5.3% (34 mmol/mol) in the controls. In paired comparison,
the mean difference of HbA1c between the case and the con-
trol children was marginally statistically significant [95% CI of
the difference 0.01–0.8% (0.1–9.0 mmol/mol); p = 0.045].
Plasma glucose values or serum C-peptide concentrations
during the five-point OGTT showed no significant differences
between the groups (Table 2).ildren with increased class II HLA-associated genetic risk for
tibodies (cases) and 10 age- and sex-matched children with
rols).
Cases all Controls all
N = 10 N = 10
9.8 (4.1) 9.9 (4.5)
7 7
4.2 (3.2) NA
6.2 (3.9) NA
22.5 (3.8) 21.4 (3.0)
6.9 (0.3) 6.9 (1.2)
2.3 (0.4) 2.0 (0.1)
ted adult BMI [23].
Table 2 – Paired comparisons between the children with increased genetic risk for type 1 diabetes mellitus and at least two
positive biochemical islet autoantibodies (cases) and their age- and sex-matched controls with genetic risk but no autoan-
tibodies (controls).
CGM N Cases
mean (SD)
Controls
mean (SD)
95% CI of
difference
p-value
Number of pairs 10
7-Day CGM glucose, mmol/l 5.4 (0.6) 4.7 (0.3) 0.1 to 1.1 0.018
Day1 CGM glucose, mmol/l 5.4 (0.5) 4.9 (0.4) 0.04 to 1.0 0.036
Night2 CGM glucose, mmol/l 5.3 (1.0) 4.4 (0.4) 0.1 to 1.7 0.026
Maximum CGM glucose, mmol/l 9.1 (2.1) 7.1 (0.4) 0.4 to 3.5 0.018
Maximum day1 CGM glucose, mmol/l 8.7 (1.8) 7.1 (0.4) 0.3 to 3.0 0.025
Maximum night2 CGM glucose, mmol/l 7.0 (1.6) 5.4 (0.4) 0.3 to 2.9 0.020
Range of CGM glucose, mmol/l 5.7 (2.3) 3.9 (0.7) 0.2 to 3.5 0.032
Range of day1 CGM glucose, mmol/l 5.3 (2.1) 3.8 (0.7) 0.1 to 3.1 0.043
Range of night2 CGM glucose, mmol/l 2.8 (1.3) 1.7 (0.3) 0.2 to 2.0 0.025
7-Day CGM glucose values SD, mmol/l 1.2 (0.5) 0.8 (0.2) 0.02 to 0.7 0.040
Day1 CGM glucose values SD, mmol/l 3.6 (1.4) 1.9 (0.4) 0.6 to 2.7 0.007
Night2 CGM glucose values SD, mmol/l 0.7 (0.4) 0.4 (0.1) 0.1 to 0.6 0.020
CGM glucose, %Time P7.8 mmol/l 5.8 (7.0) 0.4 (0.4) 0.3 to 10.4 0.040
CGM glucose, %Time P11.1 mmol/l 0.8 (1.5) 0.0 (0.0) 0.3 to 1.9 0.152
CGM glucose AUC, mmol/min/l 127.1 (13.2) 113.5 (7.1) 1.8 to 25.4 0.028
CGM glucose AUC day1, mmol/min/l 96.2 (8.7) 88.0 (5.7) 0.6 to 15.9 0.038
CGM glucose AUC night2, mmol/min/l 30.9 (5.6) 25.5 (3.1) 0.6 to 10.1 0.031
7-Day CGM glucose MAGE, mmol/l 1.2 (0.5) 0.8 (0.2) 0.04 to 7.5 0.031
SMBG, mmol/l
Number of pairs 10
7-Day SMBG glucose, mmol/l 5.3 (0.5) 5.0 (0.3) 0.2 to 0.7 0.227
Morning3 SMBG glucose, mmol/l 4.9 (0.6) 4.8 (0.4) 0.6 to 0.6 0.899
Evening3 SMBG glucose, mmol/l 5.8 (0.6) 5.3 (0.3) 0.1 to 1.0 0.029
Maximum SMBG glucose, mmol/l 8.1 (1.7) 6.6 (0.9) 0.1 to 2.9 0.038
7-Day SMBG glucose SD, mmol/l 1.3 (0.5) 0.8 (0.2) 0.1 to 0.8 0.020
HbA1c
Number of pairs 7
HbA1c% 5.7 (0.3) 5.3 (0.2) 0.01 to 0.8 0.045
HbA1c mmol/mol 39 (4) 34 (2) 0.1 to 9
OGTT
Number of pairs 5
0-Min plasma glucose, mmol/ 5.2 (0.3) 5.0 (0.1) 0.2 to 0.6 0.266
30-Min plasma glucose, mmol/l 8.4 (1.6) 7.3 (0.9) 0.8 to 3.0 0.190
60-Min plasma glucose, mmol/l 6.9 (2.7) 7.0 (2.0) 5.1 to 4.7 0.923
90-Min plasma glucose, mmol/l 6.7 (1.3) 6.3 (1.7) 2.6 to 3.6 0.702
120-Min plasma glucose, mmol/l 5.9 (1.1) 5.7 (1.3) 1.2 to 1.4 0.814
OGTT plasma glucose AUC, mmol/min/l 27.5 (4.9) 26.0 (4.9) 8.1 to 11.1 0.684
0-Min serum C-peptide, nmol/l 0.35 (0.12) 0.27 (0.11) 0.08 to 0.23 0.246
30-Min serum C-peptide, nmol/l 1.17 (0.49) 1.09 (0.50) 0.51 to 0.67 0.713
60-Min serum C-peptide, nmol/l 1.19 (0.49) 1.39 (0.74) 0.69 to 0.30 0.329
90-Min serum C-peptide, nmol/l 1.30 (0.52) 1.49 (0.91) 0.96 to 0.60 0.553
120-Min serum C-peptide, nmol/l 1.30 (0.57) 1.26 (0.71) 0.36 to 0.45 0.768
OGTT serum C-peptide AUC, nmol/min/l 4.49 (1.77) 4.73 (2.47) 1.92 to 1.45 0.719
Food records
Meal specific carbohydrate amounts and postprandial
CGM glucose values 60–120 min after the meal
Number of pairs 8
Breakfast
Carbohydrates, g 38.7 (8.2) 41.0 (5.8) 8.9 to 4.3 0.433
Mean postprandial CGM glucose, mmol/l 5.7 (1.1) 4.9 (0.3) 0.3 to 1.7 0.122
Maximum postprandial CGM glucose, mmol/l 7.5 (2.0) 6.1 (0.4) 0.3 to 3.2 0.086
Lunch
Carbohydrates, g 49.6 (10.4) 52.0 (8.9) 14.5 to 9.5 0.641
Mean postprandial CGM glucose, mmol/l 5.2 (0.6) 5.1 (0.3) 0.4 to 0.8 0.539
Maximum postprandial CGM glucose, mmol/l 6.6 (1.0) 6.2 (0.5) 0.7 to 1.5 0.444
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Table 2 – (continued)
CGM N Cases
mean (SD)
Controls
mean (SD)
95% CI of
difference
p-value
Dinner
Carbohydrates, g 52.6 (15.2) 51.1 (11.7) 8.5 to 11.4 0.741
Mean postprandial CGM glucose, mmol/l 5.5 (0.6) 5.2 (0.4) 0.1 to 0.8 0.143
Maximum postprandial CGM glucose, mmol/l 6.6 (0.5) 6.1 (0.4) 0.1 to 1.0 0.023
Supper
Carbohydrates, g 58.4 (31.8) 49.9 (17.3) 16.4 to 33.6 0.445
Mean postprandial CGM glucose, mmol/l 5.7 (0.7) 5.2 (0.3) 0.1 to 1.2 0.095
Maximum postprandial CGM glucose, mmol/l 7.1 (1.0) 6.3 (0.4) 0.2 to 1.8 0.109
Total daily carbohydrates, g 254.2 (55.1) 217.7 (50.2) 3.6 to 69.5 0.034
The mean values with standard deviations (SD), differences of means with 95% confidence interval (95% CI) and p values of paired t-tests are
presented for parameters from continuous glucose monitoring (CGM), self-monitored blood glucose values.
(SMBG) and HbA1c and variables from five-point oral glucose tolerance tests (OGTT). In addition, postprandial glucose values obtained from the
CGM and food record data during the 7-day CGM are presented.
1 Day time was defined as between 6:00 am and midnight.
2 Night time was defined as between midnight and 6:00 am.
3 The patients/families were instructed to take SMBG twice a day (morning and evening) with a blood glucose meter.
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dysglycemia
We also analyzed possible correlations between the time
since becoming positive for islet autoantibodies and various
markers of dysglycemia (HbA1c, the mean CGM glucose, the
mean AUC for CGM glucose, 7-day CGM glucose SD, MAGE,
and the time spent P7.8 mmol/l) but no correlations were
found.
3.5. Food records
The amount of carbohydrates ingested showed no significant
differences in any of the meals between the cases and con-
trols, but the total amount of daily carbohydrates including
snacks between the main meals was slightly higher in the
cases [254.2 g (SD 55.1) compared to the controls, 217.7 g (SD
50.2); 95% CI of the difference 3.6–69.4; p = 0.034] (Table 2).
4. Discussion
This study demonstrates that asymptomatic children with
preclinical type 1 diabetes mellitus defined by positivity for
multiple biochemical islet autoantibodies have higher glucose
levels and higher glycemic variation when monitored with
CGM in comparison to autoantibody-negative controls. Espe-
cially, the evening glucose values detected by CGM and also
by SMBG were higher in these children than in the controls.
In the CGM analysis the proportion of time spent at a glu-
cose level at or over 7.8 mmol/l during the 7-day follow-up
period was 5.8% in the islet autoantibody-positive children
compared to only 0.4% in the autoantibody-negative controls.
Recently, CGM data was also analyzed among autoantibody
positive children (n = 14) and autoantibody negative controls
(n = 9) in the DAISY Study [16]. According to their findings,
autoantibody-positive children spent as much as 18% of their
time at or over the cut-off value of 7.8 mmol/l [16] and
autoantibody-negative control children with increasedHLA-conferred risk also spent as much as 9% over the cut-
off limit. Previously Fox et al. studied 74 healthy individuals
without diabetes aged 9–65 years with CGM, showing that
only 0.4% of the follow-up time was spent over the cut-off
7.8 mmol/l [26], which is exactly the same as seen in the con-
trol group in our study. According to our study the cut-off
7.8 mmol/l could be a more specific marker for detection of
upcoming disease than previously reported by Steck et al.
[16]. Our findings are further supported by the results of van
Dalem et al. who also reported that increased time spent
P7.8 mmol/l during CGM may be useful in detecting early
dysglycemia in preclinical type 1 diabetes mellitus [18].
To our knowledge this is the first study to report increased
evening glucose concentrations in children with preclinical
type 1 diabetes mellitus. Higher CGM values postprandially
after dinner and higher SMBG values in the evening were
observed (Table 2). This observation is in good accordance
with the clinical experience showing that young childrenwith
established type 1 diabetes mellitus need higher basal insulin
doses in the evening [28]. SMBG samples were obtained with
no instructions related to meals, possibly interfering with
pairwise comparison. The value of evening glucose measure-
ments in the prediction of clinical diagnosis remains to be
assessed further in more detail and in larger series of subjects
with preclinical type 1 diabetes mellitus. OGTTs or mixed
meal tolerance tests performed in the evening could show dif-
ferent results than the standard tests performed in the morn-
ing after overnight fasting. New studies are needed to explore
this hypothesis.
Rather surprisingly, the postprandial CGM glucose values
after breakfast and lunch were not different between our case
and control children. This result is, however, in line with the
lack of significant differences in plasma glucose values
between the case and the control children during the OGTT.
On the basis of these observations it seems that increased
variation over 24 h and slightly elevated mean CGM glucose
levels occur in the preclinical stage of type 1 diabetes mellitus
before postprandial changes.
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Fig. 1 – Dot-plot charts of clinically relevant differences in continuous glucose monitoring (CGM) and self-monitored blood
glucose (SMBG) in asymptomatic children with multiple (P2) islet autoantibodies (cases) and age and sex-matched
autoantibody-negative controls. The mean CGM glucose (A) and area under the curve (AUC, mmol/min/l, B) during the 7-day
follow-up were significantly higher in the case group. The time spent at or above the cut-off glucose value of 7.8 mmol/l
measuredwith CGM (C), and evening SMBG values (D) were higher in the cases. Increased variation in the CGM glucose values
characterized by mean amplitude of glycemic excursion (MAGE, E) and overall standard deviation (SD) during 7-day CGM (F)
was observed in the case children compared to the controls.
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case and control children despite the small number of study
subjects included in this series. The utility of monitoring
HbA1c in the prediction of the timing of type 1 diabetes mel-
litus has been implicated by previous follow-up studies in
children at risk for overt type 1 diabetes mellitus [12,29].
In the current small series plasma glucose concentrations
in OGTTwere not different between the case and control chil-
dren. The use of OGTT in the prediction of type 1 diabetes
mellitus has been widely studied, but the sensitivity of the
test has proven rather disappointing [9,13]. Randomly taken
plasma glucose has also been assessed in studies aimed at
early recognition of type 1 diabetes mellitus with high speci-
ficity but with poor sensitivity [9]. In the current study SMBG
values were higher when considering the mean and maximal
concentrations, and also the variation in SMBG levels. The
poor sensitivity previously reported was observed whenglucose samples were taken every 3–6 months, and this could
most likely be improved simply by increasing the number of
SMBG measurements and shortening the intervals between
the measurements. It could be feasible to obtain several daily
SMBG values over a short period of time, e.g. during oneweek,
and analyze the predictive characteristics of this data.
One shortcoming of the present study is that only five of
the control children accepted to undergo an OGTT and seven
to give a sample for HbA1c analysis. One child in each group
completed the food record inadequately. Especially the OGTT
parameters may be misleading due to the small study popula-
tion. Families whose child refused to undergo the tests con-
sidered it too time consuming or inconvenient for the
participant. There is wide variation in time from detection
of autoantibodies to clinical type 1 diabetes mellitus and
emergence of dysglycemia is a rather late phenomenon
before diagnosis. It is possible that our OGTT series included
d i a b e t e s r e s e a r c h a n d c l i n i c a l p r a c t i c e 1 2 0 ( 2 0 1 6 ) 8 9 –9 6 95case children who still were at the early stage of preclinical
diabetes mellitus and therefore no differences could be seen
between our cases and the controls.
When analyzing the relationship between the time since
becoming positive for islet autoantibodies and various mark-
ers of dysglycemia no significant correlations were found. It is
difficult to draw firm conclusions because of the small sample
size of our study. However, long-term follow-up of subjects
with multiple islet autoantibodies have shown that clinical
diabetes is diagnosed at a constant rate over long time peri-
ods [5]. Some subjects with persistent islet autoimmunity
are rapid progressors and others may remain normoglycemic
for years before progressing to diabetes. Thus it would be log-
ical that the time from seroconversion does not necessarily
correlate with the markers of dysglycemia.
Monitoring of glucose metabolism may be useful in the
identification of emerging type 1 diabetes mellitus in high-
risk children, as suggested previously [16–18], and may help
the family to prepare for the diagnosis. It is important to note
that early diagnosis of type 1 diabetes mellitus prevents dia-
betic ketoacidosis at disease onset and thereby reduces the
burden for the patient and their family and shortens the ini-
tial hospitalization as well [30]. The overall prevalence of dia-
betic ketoacidosis among children with newly onset type 1
diabetes mellitus in Finland is approximately 20% [31], but
significantly lower in children with prospective follow-up
before the onset [30]. It is also possible that participation in
preclinical follow-up studies and awareness of positivity for
islet autoantibodies induces stress in the families of children
with high risk for progression to type 1 diabetes mellitus, and
in motivated subjects, CGM may provide further information
about the glycemic status and relief when interpreted
together with the study personnel. Furthermore, reliable tools
are needed for monitoring glucose metabolism during the
preclinical stage of type 1 diabetes mellitus in secondary pre-
vention studies aimed at postponing or even preventing the
disease by trying to preserve the endogenous insulin secre-
tion [32].
In conclusion, these results show that CGM, HbA1c and
evening SMBGmeasurements may be useful monitoring tools
for emerging dysglycemia in children with preclinical type 1
diabetes mellitus.Funding
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